Prostate Cancer Foundation (PCF)
Michael Milken's prostate cancer foundation, which funded the science behind abiraterone, enzalutamide and PSMA therapy and runs a precision-oncology network in US veterans' hospitals.
Overview
Founded 1993 (as CaP CURE). PCF-funded research contributed to abiraterone, enzalutamide, radium-223, PSMA imaging and radioligands, and germline testing guidance; the PCF-VA network provides genomic testing and trials to veterans; the Young Investigator awards have trained a generation of researchers. Patient resources include the Prostate Cancer Patient Guide and a Black-community outreach programme; ZERO Prostate Cancer and Movember are major partner organisations for support and awareness.
Similar pages
not linked directly; found by shared links- PathwayProstate cancer (KEGG map)
Shares Abiraterone acetate, Enzalutamide, PSMA, Lutetium-177 vipivotide tetraxetan.
- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
- PersonRahul Aggarwal
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Prostate cancer.
- TrialENZA-p
Shares Enzalutamide, Lutetium-177 vipivotide tetraxetan, PSMA PET.
- TermmCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)
Shares Abiraterone acetate, Enzalutamide, Radium-223, Prostate cancer.
- TermAndrogen receptor pathway inhibitor (ARPI)
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
- PersonJohannes Czernin
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Prostate cancer.
- TrialAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.